Inactivation of the E-cadherin cell adhesion molecule is believed critical in the development and behavior of many epithelial cancers, though mutations in the E-cadherin gene account for inactivation in only a fraction of cases. In many breast cancer lines, E-cadherin transcription is extinguished, but the role and signi®cance of alterations in trans-acting transcription factors, promoter hypermethylation, and chromatin changes remain unresolved. To gain further insights into mechanisms underlying Ecadherin inactivation in breast cancer, we analysed somatic cell hybrids resulting from pairwise fusions between breast cancer lines with intact E-cadherin transcription (E-cad+) and lines lacking E-cadherin transcription (E-cad7). All hybrid lines failed to express E-cadherin transcripts and protein, despite the fact that E-cadherin alleles from E-cad+ lines were present in the hybrids. Elements in the proximal 108 bp of the Ecadherin promoter, when present in reporter gene constructs, were sucient to direct strong transcription in E-cad+ breast lines, but displayed weak activity in Ecad7 parental lines and hybrids. E-cadherin expression could not be restored in E-cad7 lines or hybrids by treatment with a DNA demethylating agent and/or a histone deacetylase inhibitor. Our ®ndings suggest loss of E-cadherin expression in some breast cancers may be due to dominant repression of the trans-acting pathways that regulate E-cadherin transcription.
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Keywords: E-cadherin; breast cancer; somatic cell hybrid; transcription factor; gene expression; E-box The 120 kilodalton E-cadherin glycoprotein participates in homotypic, calcium-dependent, cell-cell interactions, including embryo compaction and the formation of adherens junctions between adjacent epithelial cells in various tissues (Takeichi, 1991) . In addition to its well de®ned cell adhesion function, Ecadherin has a critical role in the development and behavior of cancer cells. Treatment of Madin-Darby canine kidney (MDCK) cells with an antibody against the extracellular domain of E-cadherin increases the invasiveness of the cells in in vitro assays, and oncogene-transformed MDCK cells display increased invasive behavior in vitro and reduced or absent Ecadherin expression (Behrens et al., 1989) . Restoration of E-cadherin expression in the transformed MDCK cells abrogates their invasive behavior, though reversion to the invasive phenotype is seen following treatment with anti-E-cadherin antibodies or Ecadherin antisense RNA (Vleminckx et al., 1991) . These data have led to the designation of the Ecadherin gene as an`invasion suppressor'. Subsequent studies have shown loss of E-cadherin expression is a common ®nding in a wide spectrum of human epithelial cancers (Birchmeier and Behrens, 1994) . In breast cancer, loss of E-cadherin expression has been correlated with a more invasive phentoype and a less dierentiated histology (Siitonen et al., 1996; Gamallo et al., 1993) . Recent studies have provided more compelling evidence that E-cadherin inactivation does not simply re¯ect the cancer phenotype, but, in fact, Ecadherin inactivation has a causal role in the process. Speci®cally, germline inactivating mutations in the Ecadherin gene have been found in a number of families with inherited predisposition to gastric carcinoma, particularly those with diuse type histology (Gayther et al., 1998; Guilford et al., 1998) . In one such family, there also appears to be predisposition to breast carcinoma of the lobular type (Keller et al., 1999) .
In addition to the germline mutations, somatic mutations in E-cadherin have been detected in human cancer (Berx et al., 1995a) . Mutations in E-cadherin are most prevalent in breast carcinomas of lobular type and gastric carcinomas of diuse type, with about 50% of cancers of each of these types displaying somatic mutations inactivating both E-cadherin alleles. However, in the majority of cancers with reduced or absent E-cadherin gene and protein expression, including breast carcinomas of ductal type, mutations in Ecadherin are rare or absent, and the speci®c mechanisms underlying loss of E-cadherin expression are poorly understood. Proposed mechanisms include promoter hypermethylation (Gra et al., 1995; Yoshiura et al., 1995) , changes in chromatin structure (Hennig et al., 1995) , and alterations of speci®c transacting transcription factor pathways that regulate Ecadherin gene expression (Ji et al., 1997) . In the present study, we describe the generation and analysis of multiple independent breast cancer somatic cell hybrids. Our studies provide evidence that loss of Ecadherin expression in breast cancer is a dominant trait, mediated by alterations in factors that interact with sequence elements in the proximal 108 bp of the Ecadherin promoter.
Somatic cell hybrid lines were generated by fusions between breast cancer lines with intact E-cadherin transcription (E-cad+) and breast cancer lines with defective E-cadherin transcription (E-cad7). The MDA-MB-361 line has been shown to express Ecadherin protein and transcripts (Pierceall et al., 1995) , and it displays strong activation of reporter gene constructs containing E-cadherin promoter elements (Ji et al., 1997) . A polyclonal G418-resistant population of MDA-MB-361 cells was obtained by transfection of the cells with an expression vector containing a neomycin-resistance gene, which confers resistance to G418 in mammalian cells. The SK-BR-3 line lacks detectable E-cadherin expression due to a homozygous deletion of a large portion of the E-cadherin gene (Pierceall et al., 1995; Hiraguri et al., 1998) . Mutation of both E-cadherin alleles in SK-BR-3 precludes the need for alterations in the trans-acting pathways that regulate E-cadherin transcription, because the SK-BR-3 line retains the ability to strongly activate E-cadherin reporter gene constructs (Ji et al., 1997) . Similar to the approach with the MDA-MB-361 line, a polyclonal population of G418-resistant SK-BR-3 cells was generated by transfection. Both the Hs 578T and BT-549 breast cancer cell lines lack detectable E-cadherin expression (Pierceall et al., 1995) , and they display greatly reduced E-cadherin promoter activity (Ji et al., 1997) . Each of these two E-cad7 lines was transfected with a vector encoding resistance to the drug hygromycin in mammalian cells, and polyclonal hygromycin-resistant Hs 578T and BT-549 cell lines were subsequently derived.
The G418-resistant MDA-MB-361 line was fused to the hygromycin-resistant BT-549 line and also independently to the hygromycin-resistant Hs 578T cell line, yielding the`BM' and`HM' fusions, respectively. Similarly, the G418-resistant SK-BR-3 line was fused to the hygromycin-resistant Hs 578T line, yielding thè HSK' fusions. Hybrids were selected in both G418 and hygromycin, and individual clones resistant to both drugs were isolated and expanded into stable lines. To con®rm that the hybrid lines retained genetic material from each parental line, PCR analysis with informative polymorphic microsatellite markers was carried out on genomic DNA from the parental and hybrid lines. For example, the marker D16S2624 is located in chromosomal band 16q22.1, the region where the E-cadherin gene has been mapped (Berx et al., 1995b; Natt et al., 1989; Mansouri et al., 1988) . For the D16S2624 locus, hybrid lines retain alleles from both the E-cad+ and E-cad7 parents (Figure 1 ). Only the BM-7 line failed to retain all discernible parental alleles at the D16S2624 locus, having lost one of the two D16S2624 alleles from the MDA-MB-361 parent. Studies with additional markers from chromosomes 10 and 13 also con®rmed the hybrid nature of G418-and hygromycin-resistant lines (data not shown). Representative hybrid lines were selected for the studies described below.
Western blot studies were carried out on lysates from the parental and hybrid lines to evaluate Ecadherin protein expression. None of the hybrid lines had detectable E-cadherin expression (Figure 2a) . The absence of E-cadherin protein expression in the hybrids was con®rmed by immuno¯uorescence (data not shown). Furthermore, reverse transcription-polymerase chain reaction (RT ± PCR) analysis demonstrated the hybrid lines lacked E-cadherin transcripts ( Figure  2b ). The absence of detectable E-cadherin gene expression in the BM and HM hybrid lines establishes that extinction of E-cadherin expression is a dominant trait, because all BM and HM hybrid lines studied for Figure 1 Somatic cell hybrids retain both sets of parental alleles at the D16S2624 locus in chromosomal band 16q22.1. The D16S2624 alleles present in the BT-549, MDA-MB-361, Hs 578T, and SK-BR-3 breast cancer cell lines and representative somatic cell hybrid lines are shown in the autoradiograph. Clonal hybrid lines were isolating following fusion of a G418-resistant E-cad+ breast cancer line (i.e., MDA-MB-361 and SK-BR-3) to a hygromycin-resistant E-cad7 line (i.e., BT-549 and Hs 578T). All parental lines (American Type Culture Collection, Rockville, MD, USA) were grown in Dulbecco's Modi®ed Eagle Medium (DMEM, Life Technologies, Gaithersburg, MD, USA) with 10% fetal bovine serum (FBS, Life Technologies). The G418-resistant MDA-MB-361 and SK-BR-3 lines were generated by transfection of cells with pcDNA3.1 (Invitrogen, Carlsbad, CA, USA) and selection in medium with 0.5 mg/ml Geneticin (Life Technologies). The hygromycin-resistant BT-549 and Hs 578T lines were obtained by transfection with the hygromycin resistance vector pGRE5/EBV (Mader and White, 1993) and selection in medium containing 0.1 mg/ml hygromycin (Roche Molecular Biochemicals, Indianapolis, IN, USA). Somatic cell hybrids were prepared as described (Freshney, 1994) . Brie¯y, equal numbers of cells from each parental line were mixed and exposed for 1 min to a 1 : 1 solution of polyethylene glycol 1000 (Sigma Chemical Company, St. Louis, MO, USA) and serum-free medium, pH 7.8. The cells were then diluted in serum-free medium, centrifuged, resuspended in complete medium, and plated on tissue culture dishes. Following overnight incubation, selection for hybrids was carried out in medium containing 0.1 mg/ml hygromycin B and 0.5 mg/ml Geneticin. Multiple independent clones were isolated and expanded into hybrid lines from the following fusions: BT-549 and MDA-MB-361, yielding`BM' lines; Hs 578T and MDA-MB-361, yielding`HM' lines; and Hs 578T and SK-BR-3, yielding`HSK' lines. Hybrid lines were maintained in DMEM with 10% FBS, 0.075 mg/ml hygromycin B, and 0.5 mg/ml Geneticin. For analysis of D16S2624 polymorphic loci, genomic DNA was ampli®ed with primers from the Genome Database (http://www.gdb.org): 5'-TGAGG-CAATT-TGTTACAGAGC-3' (forward) and 5'-TAATG-TACCTGGTACCAAAAACA-3' (reverse). The forward primer was radioactively end-labeled with 32 P-g-ATP (Amersham Corp., Arlington Heights, IL, USA) using T4 polynucleotide kinase (New England Biolabs, Inc., Beverly, MA, USA). Following ampli®cation, PCR products were separated by gel electrophoresis on a denaturing polyacrylamide gel (5% polyacrylamide, 30% formamide, 6 M urea, and 16TBE) and exposed to X-OMAT-AR ®lm (Kodak, Rochester, NY, USA) E-cadherin expression retained both parental Ecadherin alleles from the MDA-MB-361 cell line (Figure 1) , a line in which we con®rmed high level expression of E-cadherin transcripts and protein (Figure 2) . Interpretation of the ®ndings from the HSK hybrid lines is complicated by the fact that the SK-BR-3 parental line has lost one copy of chromosome 16q and the remaining copy of chromosome 16q has a deletion aecting a sizeable portion of the Ecadherin locus (Pierceall et al., 1995) . Nevertheless, our prior studies (Ji et al., 1997) , as well as data presented below (®gure 3b) establish that the SK-BR-3 line retains the trans-acting factors necessary for activation of E-cadherin transcription. Consistent with the ®ndings in the BM and HM hybrid lines and the hypothesis that repression of E-cadherin is a dominant trait in breast cancer lines lacking E-cadherin expression, the HSK hybrid lines failed to activate expression from the Hs 578T E-cadherin allele(s).
We sought to document that the absence of Ecadherin expression in the somatic cell hybrid lines was due to defects in E-cadherin transcription. The hybrid lines were tested for their ability to activate reporter constructs in which E-cadherin promoter sequences were subcloned immediately upstream of the ®re¯y Luciferase gene (Ecad-luc constructs, Figure 3a ). For each cell line, luciferase activities of the various Ecadluc constructs were compared to one another and to the level of activity of a control construct where Luciferase expression is regulated by CMV promoter elements (CMV-luc). Reporter gene constructs containing as few as 108 bp of E-cadherin proximal promoter sequence had a high level of activity in E-cad+ parental lines (i.e., MDA-MB-361 and SK-BR-3), but very low activity in all hybrid lines and the E-cad7 parental lines Hs 578T and BT-549 (Figure 3b ). The reporter construct Ecad(737)-luc, which contains only 37 bp of sequence 5' to the E-cadherin transcription start site, displayed very reduced activity in all lines tested. Therefore, our ®ndings indicate sequences located between 7108 and 737 in the E-cadherin 5'
anking region are likely to bind the critical transcription factors which activate E-cadherin expression in E-cad+ breast cancer lines. Moreover, our data also imply that the proximal 108 bp of the E-cadherin promoter has a critical role in the apparent repression of E-cadherin gene expression in E-cad7 breast cancer lines. The sequence elements within the proximal 108 bp of the E-cadherin promoter include the CCAAT-box, two E-box elements that may bind basic helix ± loop ± helix proteins, and a consensus sequence for binding zinc-®nger proteins such as Sp1 and WT1 (Figure 3c ). Prior studies focusing largely on murine Ecadherin promoter elements suggest that binding of transcription factors, such as AP-2, to the proximal promoter may confer epithelial-cell speci®c expression of E-cadherin (Bussemakers et al., 1994; Behrens et al., 1991; Hennig et al., 1995 Hennig et al., , 1996 . The proximal AP-2 binding sites in the murine promoter are not conserved in the human promoter, which contains only one consensus sequence for AP-2 binding at 7117 to 7112 (Figure 3c ). As demonstrated here, this binding region lies upstream of the 108 bp E-cadherin proximal promoter region determined to be sucient for Ecadherin expression or repression in breast cancer. Hence, when considered together with previous studies that have failed to ®nd evidence of a role for AP-2 in regulation of E-cadherin expression (Ji et al., 1997) , the data imply that AP-2 is not a critical factor regulating E-cadherin expression in breast cancer. E-box factor binding may be important in E-cadherin inactivation in breast cancer, as mutation of these promotor elements results in derepression of E-cadherin reporter gene activity in some cancer cell lines, including the breast cancer cell line MDA-MB-436 (Giroldi et al., 1997) .
It has been proposed that E-cadherin gene expression is silenced in breast and other cancer cell lines as a result of hypermethylation of the E-cadherin promoter (Gra et al., 1995; Yoshiura et al., 1995) . Chromatin changes aecting the E-cadherin promoter region have also been argued to underlie silencing of E-cadherin a b Figure 2 Extinction of E-cadherin protein and gene expression in hybrids. (a) Hybrid lines lack E-cadherin protein. Whole cell lysates were prepared in radioimmunoprecipitation assay buer (Tris-buered saline, 0.5% deoxycholic acid, 0.1% SDS, and 1% NP-40) with Complete protease inhibitors (Roche). Approximately 40 mg of total protein per sample was separated by electrophoresis on SDS/polyacrylamide gels and transferred to Immobilon P membranes (Millipore Corp., Bedford, MA, USA) by semi-dry electroblotting (Transblot, Bio-Rad, Hercules, CA, USA). Immunoblot analysis was carried out with the mouse monoclonal antibody HECD-1 against E-cadherin (Zymed Laboratories, Inc., San Francisco, CA, USA), followed by horseradish peroxidase-conjugated goat anti-mouse IgG (Pierce Biochemicals, Rockford, IL, USA). To verify equal loading of the samples, the membranes were stripped and incubated with a rabbit polyclonal antibody against b-actin (Sigma), followed by a horseradish peroxidase-conjugated donkey anti-rabbit IgG antibody (Pierce). Antibody complexes were detected with the ECL Western blot kit (Amersham) and exposure to X-OMAT-AR ®lm (Kodak). The mobility of pre-stained molecular weight markers in kilodaltons is shown at the left. (b) RT ± PCR analysis demonstrates the somatic cell hybrids lack E-cadherin transcripts. RNA was isolated using TRIZOL reagent (Life Technologies) and treated with DNase I (Life Technologies). Reverse transcription was carried out with the SuperScript Preampli®cation System (Life Technologies). PCR was performed using previously described primers and cycle conditions for ampli®cation of E-cadherin transcripts (Hiraguri et al., 1998) and glyceraldehyde phosphate dehydrogenase (GAPDH) transcripts (Poola et al., 1998) . The size of the E-cadherin and GAPDH RT ± PCR products is indicated a b c Figure 3 Reduced E-cadherin promoter activity in hybrid lines. (a) Schematic representation of sequences present in Ecad-luc reporter constructs. Reporter gene constructs contain human E-cadherin 5'-¯anking sequences of varying extent subcloned into the SacI and HindIII sites of the pGL2-Basic vector (Promega Corp., Madison, WI, USA), immediately upstream of the ®re¯y Luciferase gene. For the human Ecadherin gene, the transcription start site is located 125 bp upstream of the initiating methionine. In the reporter constructs, the endogenous E-cadherin initiating methionine has been destroyed, and an additional 33 bp of¯anking sequence separate the E-cadherin sequences from the Luciferase initiating methionine. Reporter constructs extending 1359 or 368 bp 5' to the E-cadherin transcription start site have been described previously (Ji et al., 1997) . Reporter constructs containing 108 or 37 bp 5' of the E-cadherin transcription start site were generated by PCR and subcloning into the pGL2-Basic vector. The identities of the E-cadherin sequences for all constructs were con®rmed by sequence analysis. The pCH110 plasmid contains a functional lacZ gene expressed under the control of the SV40 early promoter (Pharmacia Biotech, Piscataway, NJ, USA). The control plasmid pUHC-13-3 in which the Luciferase gene is under the control of CMV promoter elements (CMV-luc) has been described previously (Gossen and Bujard, 1992) . (b) E-cadherin reporter gene activities in parental and hybrid cell lines. Cell lines growing at approximately 70% con¯uence in 6-well plates were transfected with 0.8 mg E-cadherin or pUHC-13-3 reporter construct and 0.8 mg pCH110 per well using either Lipofectin reagent (Life Technologies) or FuGene (Roche) according to the manufacturer's protocol. All transfection experiments were performed at least once in duplicate or triplicate. Cell extracts were prepared 36 ± 40 h post-transfection using reporter lysis buer (Promega), followed by determination of luciferase and b-galactosidase activities. Luciferase activities were measured in a luminometer (model TD-20E, Turner Corp., Mountain View, CA, USA). The mean and standard deviation of the reporter ratios for each construct and in parental and hybrid line analysed are shown. (c) Sequence elements in the proximal human E-cadherin promoter. The transcription start site is designated as +1 and the 5' extents of reporter constructs Ecad(7108)-luc and Ecad(737)-luc are indicated with vertical bars. Elements within the proximal 108 bp include two E-boxes, a zinc-®nger protein binding consensus for factors including Sp1 and WT1, and the CCAAT-box. An AP-2 consensus binding site lies at 7117 to 7112. A GC-rich region, that has shown dierential factor binding in some carcinomas, also lies outside the proximal 108 bp of the promoter expression (Hennig et al., 1995) . Recent studies suggest DNA methylation and chromatin condensation by histone deacetylation act synergistically to repress expression of certain genes in cancer cells, such as p16
INK4a
and MLH1 (Cameron et al., 1999) . We previously reported that a 5-day treatment with the DNA demethylating agent 5-azacytidine (5-azaC) at concentrations up to 3 mM failed to reactivate Ecadherin expression in E-cad7 breast cancer lines, including BT-549 and Hs 578T (Ji et al., 1997) . Nonetheless, to assess whether methylation, histone deacetylation, or their cooperative eects account for loss of E-cadherin expression in the hybrid lines, cells were treated with 5-azaC, the deacetylase inhibitor trichostatin A (TSA), or both agents. Restoration of Ecadherin expression could not be achieved following any of the treatments in the hybrid cell lines or parental E-cad7 lines, as assayed by immunoblot (Figure 4) . In studies carried out in parallel, we con®rmed that 5-azaC treatment was readily able to activate MHL1 expression in the RKO colon carcinoma line to levels detectable by immunoblot (data not shown). The inability to reactivate E-cadherin expression following 5-azaC and/or TSA treatment supports the view that loss of E-cadherin expression in E-cad7 breast cancer cell lines and somatic cell hybrids is not solely attributable to promoter hypermethylation and/or histone deacetylation.
In summary, our studies of somatic cell hybrids derived from the fusion of E-cad+ and E-cad7 breast cancer lines has yielded data consistent with the hypothesis that dominant repression of the normal trans-acting pathways of E-cadherin gene transcription underlies loss of E-cadherin expression in some breast cancers. Our studies have also substantially narrowed the promoter region critical for faithful regulation of E-cadherin transcription in breast cancer lines to the proximal 108 bp of the promoter upstream of the Ecadherin transcription start site. In addition to excluding AP-2 as a critical regulator of E-cadherin expression, the ®ndings also indicate the GC-rich region located between 7125 and 7113 ( Figure 3c ) and for which factor binding was seen in the E-cad+ MCF-7 line, but not in the E-cad7 MDA-MB-435 line (Hennig et al., 1995) , is most likely to have a secondary role in regulating E-cadherin expression in breast cancer. Future studies will focus on the E-box and Sp1/WT1 elements, and the identi®cation and characterization of additional regulatory elements within the proximal 108 bp of the human E-cadherin promoter. Such studies should provide important insights into the mechanisms that contribute to tumor heterogeneity and tumor progression in breast and perhaps other epithelial cancers.
